Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510567 | 0.73 | CHRNB2 (0.31) | HTR2CCHRNA4CHRNB2 | |
| SCHEMBL12430205 | 0.72 | CHRNA4 (0.30) | CHRNA4 | |
| Hydrochloric Acid SCHEMBL10345799 | 0.67 | HTR2C (0.40) | HTR2CCHRNA4CHRNB2 | |
| SCHEMBL1906255 | 0.65 | — | — | |
| SCHEMBL12430137 | 0.64 | — | — | |
| SCHEMBL12430220 | 0.61 | — | — | |
| SCHEMBL12430213 | 0.61 | HTR2C (0.34) | HTR2C | |
| SCHEMBL12430209 | 0.61 | — | — | |
| SCHEMBL4084925 | 0.61 | HTR2C (0.44) | HTR2C | |
| SCHEMBL1893652 | 0.61 | HTR2C (0.55) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981919-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981919-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| EP-1796663-B1 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | BENNANI YOUSSEF L | 2009-03-12 | — | — | US | disclosed |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | BENNANI YOUSSEF L | 2009-03-12 | — | — | US | disclosed |
| US-7423056-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423056-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | HTR5A, HTR2C, HTR2A | HTR2C 2/4885CHRNA4 207/4885CHRNB2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.